FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Merck | cancer vaccine | Gardasil

Anal cancer vax gets FDA green light

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools
  • Subscribe
  • Email
  • Print
  • Contact Author
  • Reprint

Merck has won approval for a new indication of its HPV vaccine Gardasil. The FDA gave its OK to start selling Gardasil to prevent anal cancer. Investigators presented data demonstrating that Gardasil was able to prevent anal cancer and precancerous lesions with an efficacy rate reaching up to 78 percent.

"Treatment for anal cancer is challenging; the use of Gardasil as a method of prevention is important as it may result in fewer diagnoses and the subsequent surgery, radiation or chemotherapy that individuals need to endure," said Dr. Karen Midthun, director of the FDA's Center for Biologics Evaluation and Research.

While rare, anal cancer has been a growing issue in the homosexual community. The rate of anal cancer in the homosexual community is 40 per 100,000 men, a figure that doubles among gay men who are HIV positive. More than 5,000 cases are diagnosed every year in the U.S.

- read the AFP story
- here's the report from MSNBC

Related Articles:
Expert panel recommends Gardasil for anal cancer
HPV shot provides sustained protection against pre-cancerous growths
Report: Only one-third of girls receiving HPV vax


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about Gardasil   Merck   cancer vaccine